Kewaunee Scientific Corporation (KEQU)
Kewaunee Q1 Earnings Fall Y/Y Despite International Strength
KEQU's fiscal Q1 results reflect weaker sales and LPG volumes, partly offset by stronger international profitability and cost control.
Kewaunee Scientific Posts Record $282M Revenue, Maps Fiscal 2027 Growth Investments
Kewaunee Scientific NASDAQ: KEQU reported record revenue and outlined continued investments in product development, manufacturing capacity, international expansion and potential acquisitions during its 2026 annual meeting of stockholders.
Kewaunee Scientific Q4 Earnings & Sales Fall Y/Y on Project Timing
KEQU posts lower Q4 sales and EPS as project timing and Middle East shipment delays weigh on the results despite annual revenue growth.
Kewaunee Earnings Decline Y/Y in Q3 Despite Sales Growth
KEQU posts modest sales growth in Q3 but a sharp profit decline, with domestic weakness offset partly by strong international performance.
Kewaunee's Net Sales Increase Y/Y, Earnings Decline in Q2
KEQU posts sharp Q2 sales growth, driven by strong backlog and Nu Aire, but earnings decline amid project timing volatility and higher costs.
Kewaunee Upgraded to Outperform on Nu Aire Synergies, Backlog
KEQU earns an upgrade to "Outperform" as Nu Aire integration drives sales growth, margins expand and a record backlog boosts visibility, offsetting tariff risks with proactive inventory strategies.
Kewaunee Scientific Stock Soars 47% After Q4 Earnings Beat Estimates
KEQU posts strong Q4 and FY25 results, driving a 47% stock surge as sales jump and the Nu Aire acquisition boosts growth momentum.
Kewaunee Scientific: Huge Improvement In Operational Outlook (Upgrade To Buy)
Kewaunee Scientific's strong FY2025 results, record backlog, and margin expansion signal a return to growth and improved business predictability. Adjusted EPS actually rose 28% year-over-year, once non-recurring items and acquisition costs are excluded, reflecting core operational strength. A 38% increase in backlog suggests robust revenue growth for FY2026, supporting a bullish outlook and more potential stock upside.
KEQU Reports Y/Y Earnings Decline in Q3 Despite Strong Sales Growth
Kewaunee Scientific's revenues rise 43.6% in Q3, but profits decline due to higher expenses and Nu Aire acquisition costs. Backlog hits $221.6 million.
Kewaunee Scientific: Growth Has Been Priced In After Q2 2025 Report
Kewaunee Scientific manufactures laboratory furniture and equipment, a growing market driven by the need for advancements in healthcare. Since 2022, the company has focused on improving its margins through stop selling directly in some markets where the company had to focus on producing and selling. This has been reflected in the expansion of margins, but growth has been mid-single digit, and I think it can continue like this in the future.
Kewaunee Scientific's Q2 Earnings Rise Y/Y Despite Sales Decline
KEQU reports fiscal Q2 earnings growth, driven by strong domestic demand and strategic acquisition of Nu Aire despite revenue challenges.
Zacks Initiates Coverage of Kewaunee Scientific With Neutral Recommendation
Discover why Zacks rates KEQU as "Neutral," being the first on Wall Street to initiate the coverage of the stock. Explore KEQU's strong order backlog and stable domestic growth amid international challenges and competitive pressures in the laboratory furniture market.
